Beam Therapeutics Files 8-K on Shareholder Votes
Ticker: BEAM · Form: 8-K · Filed: Jun 10, 2024
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Beam Therapeutics held a shareholder vote on June 5th. Details to follow.
AI Summary
Beam Therapeutics Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of its security holders as of June 5, 2024. The filing details the company's principal executive offices located at 238 Main Street, Cambridge, Massachusetts, 02142.
Why It Matters
This filing indicates that Beam Therapeutics held a vote of its security holders, which could pertain to important corporate decisions or governance matters.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of a shareholder vote and does not contain information about significant financial distress or operational changes.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Registrant
- June 05, 2024 (date) — Date of earliest event reported
- June 10, 2024 (date) — Date of report
- 238 Main Street, Cambridge, Massachusetts, 02142 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Beam Therapeutics' security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact proposals voted upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 05, 2024.
What is the principal executive office address for Beam Therapeutics Inc.?
The principal executive offices are located at 238 Main Street, Cambridge, Massachusetts, 02142.
What is the Commission File Number for Beam Therapeutics Inc.?
The Commission File Number for Beam Therapeutics Inc. is 001-39208.
What is the standard industrial classification for Beam Therapeutics Inc.?
The standard industrial classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 13.7 · Accepted 2024-06-10 16:30:11
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select
Filing Documents
- beam-20240605.htm (8-K) — 61KB
- 0000950170-24-071345.txt ( ) — 168KB
- beam-20240605.xsd (EX-101.SCH) — 23KB
- beam-20240605_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, Beam Therapeutics Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 19, 2024 (the "Proxy Statement"). Proposal 1 – The following nominee was elected as a Class I director to serve on the Company's board of directors until the Company's 2027 annual meeting of stockholders, and until his successor has been duly elected and qualified, based on the following votes: Nominee For Against Abstentions Broker Non-Votes Graham Cooper 49,482,793 6,520,772 1,838,647 8,424,668 Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 was ratified, based on the following votes: For Against Abstentions 66,048,930 176,166 41,784 Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstentions Broker Non-Votes 56,501,513 1,295,311 45,388 8,424,668
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Beam Therapeutics Inc. Date: June 10, 2024 By: /s/ John Evans John Evans Chief Executive Officer